tirzepatide semaglutide head to head SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions GLP-1s: Semaglutide vs. Tirzepatide vs.
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19















:max_bytes(150000):strip_icc()/GettyImages-1807240274-2c7c39cb23f34a97bb2d8620911c343d.jpg)









